Please use this identifier to cite or link to this item: https://ahro.austin.org.au/austinjspui/handle/1/30852
Full metadata record
DC FieldValueLanguage
dc.contributor.authorZhang, Xing-
dc.contributor.authorSoutto, Mohammed-
dc.contributor.authorChen, Zheng-
dc.contributor.authorBhat, Nadeem-
dc.contributor.authorZhu, Shoumin-
dc.contributor.authorEissmann, Moritz F-
dc.contributor.authorErnst, Matthias-
dc.contributor.authorLu, Heng-
dc.contributor.authorPeng, Dunfa-
dc.contributor.authorXu, Zekuan-
dc.contributor.authorEl-Rifai, Wael-
dc.date2022-
dc.date.accessioned2022-09-06T06:51:29Z-
dc.date.available2022-09-06T06:51:29Z-
dc.date.issued2022-09-
dc.identifier.citationGastroenterology 2022; 163(3): 620-636.e9en
dc.identifier.urihttps://ahro.austin.org.au/austinjspui/handle/1/30852-
dc.description.abstractHelicobacter pylori (H pylori) infection is the main risk factor for gastric cancer. The role of fibroblast growth factor receptors (FGRFs) in H pylori-mediated gastric tumorigenesis remains largely unknown. This study investigated the molecular and mechanistic links between H pylori, inflammation, and FGFR4 in gastric cancer. Cell lines, human and mouse gastric tissue samples, and gastric organoids models were implemented. Infection with H pylori was performed using in vitro and in vivo models. Western blot, real-time quantitative reverse-transcription polymerase chain reaction, flow cytometry, immunofluorescence, immunohistochemistry, chromatin immunoprecipitation, and luciferase reporter assays were used for molecular, mechanistic, and functional studies. Analysis of FGFR family members using The Cancer Genome Atlas data, followed by validation, indicated that FGFR4 messenger (m)RNA was the most significantly overexpressed member in human gastric cancer tissue samples (P < .001). We also detected high levels of Fgfr4 mRNA and protein in gastric dysplasia and adenocarcinoma lesions in mouse models. Infection with J166, 7.13, and PMSS1 cytotoxin-associated gene A (CagA)+ H pylori strains induced FGFR4 mRNA and protein expression in in vitro and in vivo models. This was associated with a concordant activation of signal transducer and activator of transcription 3 (STAT3). Analysis of the FGFR4 promoter suggested several putative binding sites for STAT3. Using chromatin immunoprecipitation assay and an FGFR-promoter luciferase reporter containing putative STAT3 binding sites and their mutants, we confirmed a direct functional binding of STAT3 on the FGFR4 promoter. Mechanistically, we also discovered a feedforward activation loop between FGFR4 and STAT3 where the fibroblast growth factor 19-FGFR4 axis played an essential role in activating STAT3 in a steroid receptor coactivator-dependent manner. Functionally, we found that FGFR4 protected against H pylori-induced DNA damage and cell death. Our findings demonstrated a link between infection, inflammation, and FGFR4 activation, where a feedforward activation loop between FGFR4 and STAT3 is established via steroid receptor coactivator in response to H pylori infection. Given the relevance of FGFR4 to the etiology and biology of gastric cancer, we propose FGFR4 as a druggable molecular vulnerability that can be tested in patients with gastric cancer.en
dc.language.isoeng
dc.subjectFGFR4en
dc.subjectGastric Canceren
dc.subjectH pylorien
dc.subjectSRCen
dc.subjectSTAT3en
dc.titleInduction of Fibroblast Growth Factor Receptor 4 by Helicobacter pylori via Signal Transducer and Activator of Transcription 3 With a Feedforward Activation Loop Involving Steroid Receptor Coactivator Signaling in Gastric Cancer.en
dc.typeJournal Articleen
dc.identifier.journaltitleGastroenterologyen
dc.identifier.affiliationOlivia Newton-John Cancer Research Instituteen
dc.identifier.affiliationDepartment of General Surgery, The First Affiliated Hospital of Nanjing Medical University, Nanjing, Jiangsu, China..en
dc.identifier.affiliationDepartment of Surgery, University of Miami Miller School of Medicine, Miami, Florida..en
dc.identifier.affiliationJiangsu Key Lab of Cancer Biomarkers, Prevention and Treatment, Jiangsu Collaborative Innovation Center for Cancer Personalized Medicine, School of Public Health, Nanjing Medical University, Nanjing, Jiangsu, China..en
dc.identifier.affiliationDepartment of Veterans Affairs, Miami Healthcare System, Miami, Florida..en
dc.identifier.affiliationDepartment of Thoracic Surgery, Jiangsu Cancer Hospital, Jiangsu Institute of Cancer Research, the Affiliated Cancer Hospital of Nanjing Medical University, Nanjing, Jiangsu, China..en
dc.identifier.affiliationSylvester Comprehensive Cancer Center, University of Miami Miller School of Medicine, Miami, Florida..en
dc.identifier.pubmedurihttps://pubmed.ncbi.nlm.nih.gov/35588797/en
dc.identifier.doi10.1053/j.gastro.2022.05.016en
dc.type.contentTexten
dc.identifier.orcid0000-0002-2855-0616en
dc.identifier.orcid0000-0002-6399-1177en
dc.identifier.pubmedid35588797
local.name.researcherEissmann, Moritz F
item.grantfulltextnone-
item.languageiso639-1en-
item.openairecristypehttp://purl.org/coar/resource_type/c_18cf-
item.cerifentitytypePublications-
item.fulltextNo Fulltext-
item.openairetypeJournal Article-
crisitem.author.deptOlivia Newton-John Cancer Research Institute-
crisitem.author.deptOlivia Newton-John Cancer Research Institute-
Appears in Collections:Journal articles
Show simple item record

Page view(s)

60
checked on Dec 11, 2024

Google ScholarTM

Check


Items in AHRO are protected by copyright, with all rights reserved, unless otherwise indicated.